文献速递中毒与环境急症消化、代谢与肾脏急症

纳曲酮在急诊科阿片类药物使用障碍患者中的潜在应用

Potential uses of naltrexone in emergency department patients with opioid use disorder.
PubMed 文献 · Clin Toxicol (Phila) · 2019-03-04
一句话结论纳曲酮(口服或每月肌注长效制剂)可能为急诊阿片过量后稳定患者提供阿片受体激动剂治疗之外的另一治疗选择,但原文未给出具体推荐等级。

本文为综述,检索MEDLINE和PubMed共618篇文献,经筛选后深入审阅65篇,并通过引文追溯追加30篇。文章回顾纳曲酮的药理学、使用历史及作为阿片类药物使用障碍药物治疗的最新研究和新方法,包括在急诊阿片过量就诊后启动的潜在可能。作者指出美沙酮和丁丙诺啡虽被广泛认为有效,但因处方者和治疗项目短缺而难以获得,且并非所有过量患者都适合阿片受体激动剂治疗,需要更多治疗选择以匹配不同需求、避免复发。

要点

  • 纳曲酮为长效阿片受体拮抗剂,有口服和每月肌注长效制剂两种剂型,原文将其列为阿片类药物使用障碍的又一治疗选择。
  • 美沙酮和丁丙诺啡(原文称MAT,更准确为medication for addiction treatment)虽被广泛认为有效,但因处方者和治疗项目短缺,即使有动机的患者也难以获得。
  • 阿片受体激动剂治疗可能并非适用于所有患者,因为许多过量就诊者并非阿片依赖,需要更多治疗选择匹配不同需求以避免复发。
  • 急诊过量就诊理想情况下应成为立即启动阿片类药物使用障碍治疗的机会,而非仅提供门诊治疗信息。
  • 作者综述了纳曲酮的药理学、使用历史及作为MAT的最新研究和新方法,包括急诊过量后启动的潜在可能。

适用人群与场景

  • 急诊科就诊的阿片类药物过量患者,稳定后考虑启动阿片类药物使用障碍治疗者。
  • 原文指出许多过量就诊者并非阿片依赖,阿片受体激动剂治疗可能并非适用于所有患者。

研究设计与关键结果

  • 本文为综述,检索MEDLINE和PubMed,初步检索共返回618篇文献,经逐一相关性评估后选65篇深入审阅,并对符合标准文献的引用进行追溯,追加30篇文献。
  • 综述内容涵盖纳曲酮药理学、使用历史、作为阿片类药物使用障碍药物治疗的最新研究及新方法,包括急诊过量就诊后启动的潜在可能。

证据类型、等级与局限

  • 证据类型:综述。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 原文指出急诊过量就诊理想情况下应成为立即启动阿片类药物使用障碍治疗的机会,而非仅提供门诊治疗信息。
  • 原文指出纳曲酮可能代表另一种治疗选择,用于匹配不同患者需求以避免复发。
  • 原文指出美沙酮和丁丙诺啡虽被广泛认为有效,但因处方者和治疗项目短缺而难以获得,且可能并非适用于所有患者。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

Introduction: Despite widespread recognition of the opioid crisis, opioid overdose remains a common reason for Emergency Department (ED) utilization. Treatment for these patients after stabilization often involves the provision of information for outpatient treatment options. Ideally, an ED visit for overdose would present an opportunity to start treatment for opioid use disorder (OUD) immediately. Although widely recognized as effective, opioid agonist therapy with methadone and buprenorphine commonly referred to as "medication-assisted therapy" but more correctly as "medication for addiction treatment" (MAT), can be difficult to access even for motivated individuals due to shortages of prescribers and treatment programs. Moreover, opioid agonist therapy may not be appropriate for all patients, as many patients who present after overdose are not opioid dependent. More treatment options are required to successfully match patients with diverse needs to an optimal treatment plan in order to avoid relapse. Naltrexone, a long-acting opioid antagonist, available orally and as a monthly extended-release intramuscular injection, may represent another treatment option. Methods: We conducted a literature search of MEDLINE and PubMed. We aimed to capture references related to naltrexone and is use as MAT for OUD, as well as manuscripts that discussed naltrexone in comparison toother agents used for MAT, opioid detoxification, and naltrexone metabolism. Our initial search logic returned a total of 618 articles. Following individual evaluation for relevance, we selected 65 for in-depthreview. Manuscripts meeting criteria were examined for citations meriting further review, leading to the addition of 30 manuscripts Conclusions: Here, we review the pharmacology of naltrexone as it relates to OUD, its history of use, and highlight recent studies and new approaches for use of the drug as MAT including its potential initiation after ED visit for opioid overdose.

来源:Clin Toxicol (Phila),查看原文。版权归原作者所有。

参考来源

  1. Bradley ES, Liss D, Carreiro SP, et al. Potential uses of naltrexone in emergency department patients with opioid use disorder. Clin Toxicol (Phila). 2019. PMID: 30831039. doi:10.1080/15563650.2019.1583342

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。